Text version
Hi! David Rosenberg here for the Psychopharmacology Institute. In this CAP, or Child and Adolescent Psychiatry Smart Take, we’ll examine another stimulant medication shown to be superior to placebo and examine its long-term efficacy and tolerability in a follow-up, 1-year, open-label safety study. There have been a whole lot of placebo-controlled trials of new stimulants with a chemical tweak here and another chemical tweak there. Kind of like the Old MacDonald song, “Here a chicken, there a chicken, everywhere a chicken, Old MacDonald had a farm.” Although I do not intend to be flippant, it seems that every week there’s a new stimulant trial showing superiority over placebo. In this particular instance, the trials demonstrate superiority over placebo in children and adolescents with ADHD. However, a more meaningful approach—which isn’t being pursued either here or elsewhere—is active comparator trials. These trials would determine whether 1 of these new methylphenidate compounds
Unlock this CAP Smart Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended, Gold extended, Gold – fr, Silver – fr, Silver extended – fr or Gold extended – fr Member.
Already have an account? Sign in
